Technology News and Research

RSS

Genetix Pharmaceuticals announces completion of $35M Series B financing

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

MGHS and McKesson to deploy EHR technology throughout Michigan’s Upper Peninsula

Dedicated to keeping area physicians ahead of the curve, Marquette General Health System (MGHS) will work with McKesson to deploy electronic health record (EHR) technology designed to help improve patient care throughout Michigan’s Upper Peninsula. The region’s only tertiary care provider plans to use McKesson’s Practice Partner® EHR, which integrates with the McKesson Paragon® hospital information system (HIS) currently supporting Marquette General Hospital and its 30 owned physician practices.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

New SpermCheck Fertility home test kit for sperm level measurement

Infertility affects between 10 and 15 percent of couples worldwide. Surprisingly, problems with male fertility account for approximately 50 percent of infertility cases.

12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

$Stryker's Orthopaedics Division releases three new plating systems for bone fracture repair$

Stryker's Orthopaedics Division releases three new plating systems for bone fracture repair

Stryker Corporation's Orthopaedics Division today announced the release of three new plating systems: the VariAx Elbow Locking Plate System, the VariAx Fibula Locking Plate System and the AxSOS Extremity Plating System, which are all designed to expand the range of treatment options for bone fracture repair.

From Stryker 12 Mar 2010

Study shows 95% of healthcare enterprises rely on smartphones for work

“Managing and Securing Mobile Healthcare Data and Devices,” a commissioned technology adoption profile conducted by Forrester Consulting on behalf of Fiberlink Communications Corporation was released today with findings on the top needs of healthcare IT leaders. With 95% of healthcare enterprises relying on smartphones for work, this industry is one of the most mobile across all verticals.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Decision making: Replays in hippocampus part of complex process

Replaying recent events in the area of the brain called the hippocampus may have less to do with creating long-term memories, as scientists have suspected, than with an active decision-making process, suggests a new study by researchers at Carnegie Mellon University and the University of Minnesota Medical School.

12 Mar 2010

TechniScan utilizes NVIDIA Tesla GPUs in WBU system for diagnostic breast imaging

TechniScan, Inc. is featured on NVIDIA's recently posted blog about speeding the amount of time it takes to get breast imaging results into the hands of doctors and patients. NVIDIA is the world leader in visual computing technologies and inventor of the graphics processing unit.

12 Mar 2010

Regence selects Health Integrated to provide medical management services for its members

Regence has chosen Health Integrated, a leading provider of Health Management Solutions, to provide integrated medical management services that will help improve member health and reduce costs for its members . Regence is the largest health insurer in the Northwest/Intermountain Region, serving Oregon, Utah, Idaho and select counties in Washington.

12 Mar 2010

Entrada receives venture funding to market health care platform nationwide

After the successful rollout of its clinical documentation and communication platform in the Southeast, Entrada has received venture funding to market the solution nationally to medical groups, hospitals, and electronic health record companies.

12 Mar 2010

CardioGenics Holdings offers further update on Merck Chimie agreement status

CardioGenics Holdings Inc., a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, announced today a further update regarding the status of its agreement with Merck Chimie s.a.s.

12 Mar 2010

Bayer HealthCare Pharmaceuticals' ciprofloxacin DPI granted FDA orphan drug designation for CF treatment

Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.

12 Mar 2010

Microchip Biotechnologies renamed as IntegenX

Microchip Biotechnologies, a maker of automated microscale biotech laboratory systems, today announced that it has changed its business name to IntegenX. The new name articulates the company's focus on integrating sample preparation and analysis technologies into complete products that address generic problems shared by life science and biotechnology research laboratories worldwide.

12 Mar 2010

Sigma-Aldrich announces global licensing agreement with CSIRO for RAFT agents

Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.

12 Mar 2010

Restrictions on physician work hours may lead to more miscommunication

As shifts change in a hospital, outgoing physicians must "hand off" important information to their replacements in a brief meeting. But a new study of this hand-off process finds that the most important information is not fully conveyed in a majority of cases, even as physicians rate their communication as successful.

11 Mar 2010

Helix BioMedix enters into distribution agreement with RubyDerm Bio

Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

11 Mar 2010